Venture Capital

Nextalia: Private Equity II Reaches Over €1.1 Billion First Close From More Than 200 Investors

By Amit Chowdhry ● Aug 6, 2026

Nextalia has completed the first close of Nextalia Private Equity II at more than €1.1 billion, securing commitments from over 200 investors within five months.

Proxy Foods AI Raises $6 Million Seed Round To Expand AI-Native Food R&D Platform

By Amit Chowdhry ● Aug 6, 2026

Proxy Foods AI has raised $6 million in seed funding to expand its artificial intelligence platform for food and beverage research and development. The round was led by Ted Leonsis, founder, chairman, managing partner and CEO of Monumental Sports & Entertainment, with lead participation from Robert G. Hisaoka and SWaN & Legend Venture Partners.

LifeMine Therapeutics Raises $263 Million To Advance LIFE-001 For Organ Transplantation

By Amit Chowdhry ● Aug 6, 2026

LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of LIFE-001 and advance its broader pipeline of transplantation and immunology therapies. The financing includes an oversubscribed $188 million Series E round led by Milky Way Investments. New investors included Bezos Expeditions, Gates Frontier and RA Capital Management, while GV, LoLa Capital Partners, GlaxoSmithKline, Invus and ARCH Venture Partners continued their support.

Vedanta Biosciences Raises $60 Million To Advance Phase 3 VE303 Study

By Amit Chowdhry ● Aug 6, 2026

Vedanta Biosciences has secured $60 million in funding to advance its pivotal Phase 3 RESTORATiVE303 study evaluating VE303 for the prevention of recurrent Clostridioides difficile infection. The financing includes a $40 million investment round led by existing investors AMR Action Fund and BNP Paribas Asset Management Alts. Vedanta received approximately $18 million during the first quarter and another $22 million during the second quarter.

Sapiom Raises $35 Million Series A To Scale AI Agent Infrastructure

By Amit Chowdhry ● Aug 6, 2026

Sapiom has raised $35 million in Series A funding to expand its infrastructure platform for deploying, operating and scaling artificial intelligence agents.

Opal Therapeutics Secures $1.25 Million NSF Award To Expand Uterine Organoid Platform

By Amit Chowdhry ● Aug 6, 2026

Opal Therapeutics has secured a $1.25 million Phase II award through the National Science Foundation’s Small Business Innovation Research program.

SkinBit Raises $6 Million Pre-Seed To Expand Full-Body Skin Cancer Screening Platform

By Amit Chowdhry ● Aug 6, 2026

SkinBit has raised $6 million in pre-seed funding to develop and deploy its full-body skin imaging system for skin cancer screening. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital participated in the round. The investor group also included Lyft co-founder Logan Green and nine board-certified dermatologists.

Aurelius Systems Raises $40 Million Series A To Scale Archimedes Counter-Drone Platform

By Amit Chowdhry ● Aug 6, 2026

Aurelius Systems has raised $40 million in Series A funding to advance its Archimedes autonomous counter-drone platform and expand manufacturing operations. Draper Associates and KAS Venture Partners co-led the round. Other participants included General Catalyst, Hanwha Asset Management Venture Fund, Outlander, Alumni Ventures, Bravo Victor Venture Capital, Detroit Venture Partners and Decisive Point.

Glucotrack Secures $5.5 Million Financing Through Equity And Convertible Debt

By Amit Chowdhry ● Aug 6, 2026

Glucotrack has entered into definitive agreements for approximately $5.5 million in financing from institutional investors. The deal consists of a $2 million equity financing and a $3.5 million follow-on investment in the form of convertible debt.

Cross-Border Impact Ventures: Women’s And Children’s Health Technology Fund II Reaches $58 Million First Close Toward $125 Million Target

By Amit Chowdhry ● Aug 6, 2026

Cross-Border Impact Ventures has completed a $58 million first close for its second women’s and children’s health-focused investment fund. The Women’s and Children’s Health Technology Fund II is targeting a total fund size of $125 million. Cross-Border Impact Ventures expects to complete the final close in 2027.